AB126594

Anti-FOXO4/AFX (phospho S262) antibody [EPR2315(2)]

RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(7 Publications)

Rabbit Recombinant Monoclonal FOXO4/AFX phospho S262 antibody. Suitable for WB and reacts with Human samples. Cited in 7 publications.

View Alternative Names

AFX, AFX1, MLLT7, FOXO4, Forkhead box protein O4, Fork head domain transcription factor AFX1

2 Images

Unknown

Western blot - Anti-FOXO4/AFX (phospho S262) antibody [EPR2315(2)] (AB126594)

All lanes:

Western blot - Anti-FOXO4/AFX (phospho S262) antibody [EPR2315(2)] (ab126594) at 1/10000 dilution

Lane 1:

Cell lysate from FOXO4 transfected 293T at 10 µg

Lane 2:

Cell lysate from FOXO4 transfected 293T treated with Alkaline Phosphatase at 10 µg

Lane 3:

Cell lysate from non-transfected 293T at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP at 1/2000 dilution

Predicted band size: 53 kDa,7 kDa

Observed band size: 9 kDa

false

OI-RD Scanning - Anti-FOXO4/AFX (phospho S262) antibody [EPR2315(2)] (AB126594)

OI-RD Scanning

Unknown

OI-RD Scanning - Anti-FOXO4/AFX (phospho S262) antibody [EPR2315(2)] (AB126594)

We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.

Carrier free

Anti-FOXO4/AFX (phospho S262) antibody [EPR2315(2)] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR2315(2)

Isotype

IgG

Carrier free

Reacts with

Human

Applications

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

This antibody only detects FOXO4 / AFX phosphorylated at serine 262.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/10000 - 1/50000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Mouse": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Rat": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

style

left-column

Product details

This antibody was developed as part of a collaboration between the University of Utrecht, Netherlands and the lab of Tobias Dansen.

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Storage information

Stable for 12 months at -20°C

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

FOXO4 also known as AFX is part of the FoxO family of transcription factors and weighs about 74 kDa. It operates as an important player in transcriptional regulation by binding to specific DNA sequences. This protein modulates gene expression linked to apoptosis cell cycle regulation and oxidative stress resistance. FOXO4 commonly expresses in tissues like the liver skeletal muscle and adipose tissue where it carries out critical cellular functions.

Biological function summary

This protein influences processes essential for cell survival and metabolism. FOXO4 forms part of the larger forkhead box family of transcription factors. Inside cells it regulates genes involved in mechanisms such as gluconeogenesis and immune responses. It can also interact with other proteins like 14-3-3 which helps control its nuclear-cytoplasmic shuttling impacting its activity.

Pathways

FOXO4 becomes an integral part of the insulin signaling and oxidative stress response pathways. In the insulin pathway FOXO4 activity suppresses in response to insulin signals that trigger the PI3K/Akt pathway. Akt phosphorylates FOXO4 disallowing it from entering the nucleus. FOXO4 relates closely with FOXO1 and FOXO3 within these pathways where their coordinated activities help maintain energy homeostasis and cellular stress responses.

FOXO4 involvement becomes apparent in conditions such as diabetes and cancer. In diabetes disrupted insulin signaling impacts FOXO4 activity impairing glucose metabolism. In cancer FOXO4's role in cell cycle arrest and apoptosis associates it with tumor suppression and progression. Its interaction with proteins like p53 influences cellular responses to oncogenic stress marking FOXO4 as a significant factor in oncological research.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Transcription factor involved in the regulation of the insulin signaling pathway. Binds to insulin-response elements (IREs) and can activate transcription of IGFBP1. Down-regulates expression of HIF1A and suppresses hypoxia-induced transcriptional activation of HIF1A-modulated genes. Also involved in negative regulation of the cell cycle. Involved in increased proteasome activity in embryonic stem cells (ESCs) by activating expression of PSMD11 in ESCs, leading to enhanced assembly of the 26S proteasome, followed by higher proteasome activity.

See full target information FOXO4 phospho S262

style

left-column

Publications (7)

Recent publications for all applications. Explore the full list and refine your search

iScience 26:107540 PubMed37649699

2023

mTORC2 orchestrates monocytic and granulocytic lineage commitment by an ATF5-mediated pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yang Zhao,Chenxu Zhao,Han Guo,Zhaoqi Zhang,Huawen Xu,Mingpu Shi,Yanan Xu,Dong Wei,Yong Zhao

Development (Cambridge, England) 150: PubMed36607602

2023

The AKT1-FOXO4 axis reciprocally regulates hemochorial placentation.

Applications

Unspecified application

Species

Unspecified reactive species

Keisuke Kozai,Ayelen Moreno-Irusta,Khursheed Iqbal,Mae-Lan Winchester,Regan L Scott,Mikaela E Simon,Masanaga Muto,Marc R Parrish,Michael J Soares

Molecular medicine reports 25: PubMed35475577

2022

Atorvastatin regulates vascular smooth muscle cell phenotypic transformation by epigenetically modulating contractile proteins and mediating Akt/FOXO4 axis.

Applications

Unspecified application

Species

Unspecified reactive species

Xinping Du,Zhiyuan Sun,Zhongnan Cao,Xiuhong Zhou,Dong Wang,Kuan Wang,Xuebin Li,Guoxing Zuo

Phytotherapy research : PTR 35:1495-1507 PubMed33103284

2020

Resveratrol inhibits bile acid-induced gastric intestinal metaplasia via the PI3K/AKT/p-FoxO4 signalling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Wenquan Lu,Zhen Ni,Shuqin Jiang,Mingfu Tong,Jian Zhang,Jing Zhao,Chenchen Feng,Qiaoyu Jia,Jingyun Wang,Tingting Yao,Hanbing Ning,Yongquan Shi

EMBO reports 21:e48796 PubMed32149459

2020

LncRNA GUARDIN suppresses cellular senescence through a LRP130-PGC1α-FOXO4-p21-dependent signaling axis.

Applications

Unspecified application

Species

Unspecified reactive species

Xuedan Sun,Rick Francis Thorne,Xu Dong Zhang,Miao He,Jinming Li,Shanshan Feng,Xiaoying Liu,Mian Wu

Scientific reports 8:9101 PubMed29904119

2018

WNK1 regulates skeletal muscle cell hypertrophy by modulating the nuclear localization and transcriptional activity of FOXO4.

Applications

Unspecified application

Species

Unspecified reactive species

Shintaro Mandai,Takayasu Mori,Naohiro Nomura,Taisuke Furusho,Yohei Arai,Hiroaki Kikuchi,Emi Sasaki,Eisei Sohara,Tatemitsu Rai,Shinichi Uchida

Oncogene 37:363-376 PubMed28945225

2017

Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis.

Applications

Species

Unspecified reactive species

F Zhang,D M Virshup,J K Cheong

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-FOXO4/AFX (phospho S262) antibody [EPR2315(2)]

Western blot - Anti-FOXO4/AFX (phospho S262) antibody [EPR2315(2)] (AB126594)

OI-RD Scanning - Anti-FOXO4/AFX (phospho S262) antibody [EPR2315(2)] (AB126594)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Specificity

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (7)

Product promise